Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC's Generic Market Analysis Forcing Divestures Even In Diverse Categories

This article was originally published in The Pink Sheet Daily

Executive Summary

Hikma must divest rights to three drugs under Roxane Labs deal as Federal Trade Commission aims to preserve as many as five competitors in some markets.

You may also be interested in...



Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth

Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.

Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation

Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.

Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials

Cidara developed the antifungal for candidemia/invasive candidiasis pursuant to the FDA’s 2017 ‘Unmet Need guidance,’ which provides an avenue for approval with a 'limited use' indication based on a streamlined development program. Some of the guidance recommendations also have been leveraged under the LPAD pathway.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel